Top

Published in:

Open Access 01-12-2018 | Study protocol

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study

Authors: Nienke Legdeur, Maryam Badissi, Stephen F. Carter, Sophie de Crom, Aleid van de Kreeke, Ralph Vreeswijk, Marijke C. Trappenburg, Mardien L. Oudega, Huiberdina L. Koek, Jos P. van Campen, Carolina J. P. W. Keijsers, Chinenye Amadi, Rainer Hinz, Mark F. Gordon, Gerald Novak, Jana Podhorna, Erik Serné, Frank Verbraak, Maqsood Yaqub, Arjan Hillebrand, Alessandra Griffa, Neil Pendleton, Sophia E. Kramer, Charlotte E. Teunissen, Adriaan Lammertsma, Frederik Barkhof, Bart N. M. van Berckel, Philip Scheltens, Majon Muller, Andrea B. Maier, Karl Herholz, Pieter Jelle Visser

Published in: BMC Geriatrics | Issue 1/2018

Abstract

Background

The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study.

Methods

The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer’s Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures.

Discussion

The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration.

Trial registration

Nederlands Trial Register NTR5867. Registered 20 May 2016.

Available only for authorised users

Bullain SS, Corrada MM. Dementia in the oldest old. Continuum (Minneap Minn). 2013;19:457–69. https://doi.org/10.1212/01.CON.0000429172.27815.3f.CrossRef

Rivoirard R, Chargari C, Trone J-C, Falk AT, Guy J-B, Eddekaoui H, et al. General management of nonagenarian patients: a review of the literature. Swiss Med Wkly. 2014;144:w14059.PubMed

United Nations, Department of Economic and Social Affairs, Population Division, Population Estimates and Projections Section. World Population Prospects, the 2012 Revision. Population by Age Groups- Both Sexes. Medium-fertility variant, 2010–2100. n.d. http://esa.un.org/wpp/ExcelData/population.htm (accessed May 11, 2015).

Corrada M, Brookmeyer R, Berlau D, Paganini-Holl A, Kawas C. Prevalence of dementia after age 90 results from the 90+ study. Neurology. 2008;71:337–44.CrossRef

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3:186–91. https://doi.org/10.1016/j.jalz.2007.04.381.CrossRefPubMed

Rasmussen SH, Andersen-Ranberg K, Thinggaard M, Jeune B, Skytthe A, Christiansen L, et al. Cohort profile: the 1895, 1905, 1910 and 1915 Danish birth cohort studies - secular trends in the health and functioning of the very old. Int J Epidemiol. 2017;46(6):1746. https://doi.org/10.1093/ije/dyx053.CrossRefPubMed

Corrada MM, Berlau DJ, Kawas CH. A population-based clinicopathological study in the oldest-old: the 90+ study. Curr Alzheimer Res. 2012;9:709–17.CrossRef

Formiga F, Ferrer A, Chivite D, Rubio-Rivas M, Cuerpo S, Pujol R. Predictors of long-term survival in nonagenarians: the NonaSantfeliu study. Age Ageing. 2011;40:111–6. https://doi.org/10.1093/ageing/afq127.CrossRefPubMed

van Exel E, Gussekloo J, Houx P, de Craen AJM, Macfarlane PW, der Wiel AB, et al. Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus study. Atherosclerosis. 2002;165:353–9.CrossRef

10.

Collerton J, Barrass K, Bond J, Eccles M, Jagger C, James O, et al. The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatr. 2007;7:14. https://doi.org/10.1186/1471-2318-7-14.CrossRefPubMedPubMedCentral

11.

Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75:1195–202. https://doi.org/10.1212/WNL.0b013e3181f4d7f8.CrossRefPubMed

12.

Skoog I, Nilsson L, Palmertz B, Andreasson L-A, Svanborg A. A population-based study of dementia in 85-years-olds. N Engl J Med. 1993;328:153–8.CrossRef

13.

Formiga F, Ferrer A, Megido MJ, Chivite D, Badia T, Pujol R. Low Co-Morbidity, Low Levels of Malnutrition, and Low Risk of Falls in a Community-Dwelling Sample of 85-Year-Olds Are Associated with Successful Aging: The Octabaix Study. Rejuvenation Res. 2011;14:309–14. https://doi.org/10.1089/rej.2010.1131.CrossRefPubMed

14.

Bergdahl E, Gustavsson JMC, Kallin K, Wågert PVH, Lundman B, Bucht G, et al. Depression among the oldest old: the Umea 85+ study. Int Psychogeriatrics. 2005;17:557–75. https://doi.org/10.1017/S1041610205002267.CrossRef

15.

Huang C-Q, Dong B-R, Wu H-M, Zhang Y-L, Wu J-H, Lu Z-C, et al. Association of cognitive impairment with serum lipid/lipoprotein among Chinese nonagenarians and centenarians. Dement Geriatr Cogn Disord. 2009;27:111–6. https://doi.org/10.1159/000194660.CrossRefPubMed

16.

Paganini-Hill A, Kawas CH, Corrada MM. Lifestyle factors and dementia in the oldest-old: the 90+ study. Alzheimer Dis Assoc Disord. 2016;30:21–6. https://doi.org/10.1097/WAD.0000000000000087.CrossRefPubMedPubMedCentral

17.

Rastas S, Pirttila T, Mattila K, Verkkoniemi A, Juva K, Niinisto L, et al. Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study. Neurobiol Aging. 2010;31:1–7. https://doi.org/10.1016/j.neurobiolaging.2008.02.020.CrossRefPubMed

18.

Skoog I, Börjesson-Hanson A, Kern S, Johansson L, Falk H, Sigström R, et al. Decreasing prevalence of dementia in 85-year olds examined 22 years apart: the influence of education and stroke. Sci Rep. 2017;7:1–8. https://doi.org/10.1038/s41598-017-05022-8.CrossRef

19.

Harrison SL, Stephan BCM, Siervo M, Granic A, Davies K, Wesnes KA, et al. Is there an association between metabolic syndrome and cognitive function in very old adults? The Newcastle 85+ study. J Am Geriatr Soc. 2015;63:667–75. https://doi.org/10.1111/jgs.13358.CrossRefPubMed

20.

van Exel E, de Craen AJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, Macfarlane PW, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 2002;51:716–21. https://doi.org/10.1002/ana.10220.CrossRefPubMed

21.

Formiga F, Ferrer A, Chivite D, Pinto X, Cuerpo S, Pujol R. Serum high-density lipoprotein cholesterol levels, their relationship with baseline functional and cognitive status, and their utility in predicting mortality in nonagenarians. Geriatr Gerontol Int. 2011;11:358–64. https://doi.org/10.1111/j.1447-0594.2010.00681.x.CrossRefPubMed

22.

Formiga F, Ferrer A, Chivite D, Pinto X, Badia T, Padros G, et al. Serum high-density lipoprotein cholesterol levels correlate well with functional but not with cognitive status in 85-year-old subjects. J Nutr Health Aging. 2012;16:449–53.CrossRef

23.

Sabayan B, Oleksik AM, Maier AB, van Buchem MA, Poortvliet RK, de Ruijter W, et al. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus study. J Am Geriatr Soc. 2012;60:2014–9. https://doi.org/10.1111/j.1532-5415.2012.04203.x.CrossRefPubMed

24.

Corrada MM, Hayden KM, Paganini-Hill A, Bullain SS, DeMoss J, Aguirre C, et al. Age of onset of hypertension and risk of dementia in the oldest-old: the 90+ study. Alzheimers Dement. 2017;10:1–8. https://doi.org/10.1016/j.jalz.2016.09.007.CrossRef

25.

Molander L, Gustafson Y, Lovheim H. Longitudinal associations between blood pressure and dementia in the very old. Dement Geriatr Cogn Disord. 2010;30:269–76. https://doi.org/10.1159/000320252.CrossRefPubMed

26.

Molander L, Gustafson Y, Lövheim H. Low blood pressure is associated with cognitive impairment in very old people. Dement Geriatr Cogn Disord. 2010;29:335–41. https://doi.org/10.1159/000289821.CrossRefPubMed

27.

Huang C-Q, Dong B-R, Zhang Y-L, Wu H-M, Liu Q-X, Flaherty JH. Cognitive impairment and hypertension among Chinese nonagenarians and centenarians. Hypertens Res. 2009;32:554–8. https://doi.org/10.1038/hr.2009.72.CrossRefPubMed

28.

Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and dementia - a comprehensive review. Ther Adv Neurol Disord. 2009;2:241–60. https://doi.org/10.1177/1756285609103483.CrossRefPubMedPubMedCentral

29.

Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–81. https://doi.org/10.1212/01.Wnl.0000149519.47454.F2.CrossRefPubMed

30.

van den Berg E, de Craen AJ, Biessels GJ, Gussekloo J, Westendorp RG. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia. 2006;49:2015–23. https://doi.org/10.1007/s00125-006-0333-1.CrossRefPubMed

31.

Formiga F, Ferrer A, Padros G, Corbella X, Cos L, Sinclair AJ, et al. Diabetes mellitus as a risk factor for functional and cognitive decline in very old people: the Octabaix study. J Am Med Dir Assoc. 2014;15:924–8.CrossRef

32.

Rastas S, Verkkoniemi A, Polvikoski T, Juva K, Niinisto L, Mattila K, et al. Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke. 2007;38:1454–60. https://doi.org/10.1161/STROKEAHA.106.477299.CrossRefPubMed

33.

Diniz BS, Butters MA, Albert SM, Dew MA. Reynolds 3rd CF. late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013;202:329–35. https://doi.org/10.1192/bjp.bp.112.118307.CrossRefPubMedPubMedCentral

34.

Stek ML, Gussekloo J, Beekman AT, Van Tilburg W, RGJ W. Prevalence, correlates and recognition of depression in the oldest old: the Leiden 85-plus study. J Affect Disord. 2004;78:193–200. https://doi.org/10.1016/S0165-0327(02)00310-5.CrossRefPubMed

35.

Jirong Y, Changquan H, Hongmei W, Bi-Rong D. Association of sleep quality and dementia among long-lived Chinese older adults. Age (Omaha). 2013;35:1423–32. https://doi.org/10.1007/s11357-012-9432-8.CrossRef

36.

Gildner TE, Liebert MA, Kowal P, Chatterji S, Snodgrass JJ. Associations between Sleep Duration , Sleep Quality , and Cognitive Test Performance among Older Adults from Six Middle Income Countries : Results from the Study on Global. J Clin Sleep Med. 2014;10:613–21.PubMedPubMedCentral

37.

Gussekloo J, de Craen AJM, Oduber C, van Boxtel MPJ, Westendorp RGJ. Sensory impairment and cognitive functioning in oldest-old subjects: the Leiden 85+ study. Am J Geriatr Psychiatry. 2005;13:781–6. https://doi.org/10.1097/00019442-200509000-00006.CrossRefPubMed

38.

Jefferis JM, Collerton J, Taylor JP, Jagger C, Kingston A, Davies K, et al. The impact of visual impairment on mini-mental state examination scores in the Newcastle 85+ study. Age Ageing. 2012;41:565–8. https://doi.org/10.1093/ageing/afs042.CrossRefPubMedPubMedCentral

39.

Roberts RO, Christianson TJH, Kremers WK, Mielke MM, Machulda MM, Vassilaki M, et al. Association between olfactory dysfunction andAmnestic mild cognitive impairment and Alzheimer disease dementia. JAMA Neurol. 2016;73:481. https://doi.org/10.1001/jamaneurol.2015.2952.CrossRef

40.

Taekema DG, Gussekloo J, Maier AB, Westendorp RG, de Craen AJ. Handgrip strength as a predictor of functional, psychological and social health. A prospective population-based study among the oldest old. Age Ageing. 2010;39:331–7. https://doi.org/10.1093/ageing/afq022.CrossRefPubMed

41.

Bullain SS, Corrada MM, Perry SM, Kawas CH. Sound body sound mind? Physical performance and the risk of dementia in the oldest-old: the 90+ study. J Am Geriatr Soc. 2016;64:1408–15.CrossRef

42.

Bathum L, Christiansen L, Jeune B, Vaupel J, McGue M, Christensen K. Apolipoprotein E genotypes: relationship to cognitive functioning, cognitive decline, and survival in nonagenarians. J Am Geriatr Soc. 2006;54:654–8.CrossRef

43.

Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, et al. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet. 2002;107:201–8.CrossRef

44.

Corrada MM, Paganini-Hill A, Berlau DJ, Kawas CH. APOE genotype, dementia and mortality in the oldest-old: the 90+ study. Alzheimers Dement. 2013;9:12–8. https://doi.org/10.1016/j.jalz.2011.12.004.CrossRefPubMed

45.

Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, et al. Apolipoprotein E, cognitive function, and dementia in a general population aged 85 years and over. Int Psychogeriatrics. 2000;72:379–87.CrossRef

46.

Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, et al. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology. 2000;54:412–5.CrossRef

47.

Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–217. https://doi.org/10.1016/j.cell.2013.05.039.CrossRefPubMedPubMedCentral

48.

Waaijer MEC, Parish WE, Strongitharm BH, Van Heemst D, Slagboom PE, De Craen AJM, Sedivy JM, Westendorp RGJ, Gunn DA, Maier AB. The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell. 2012;11:722-5. https://doi.org/10.1111/j.1474-9726.2012.00837.x.CrossRef

49.

Schram MT, Euser SM, de Craen AJM, Witteman JC, Frolich M, Hofman A, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55:708–16.CrossRef

50.

Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement. 2009;5:318–23. https://doi.org/10.1016/j.jalz.2009.04.1230.CrossRefPubMedPubMedCentral

51.

Kravitz BA, Corrada MM, Kawas CH. High levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from the 90+ study. J Am Geriatr Soc. 2009;57:641–6. https://doi.org/10.1111/j.1532-5415.2009.02169.x.CrossRefPubMedPubMedCentral

52.

Martin-Ruiz CM, Gussekloo J, van Heemst D, von Zglinicki T, Westendorp RGJ. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4:287–90. https://doi.org/10.1111/j.1474-9726.2005.00171.x.CrossRefPubMed

53.

Jansen WJ, Ossenkoppele R, Knol D, Al E. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924–38. https://doi.org/10.1001/jama.2015.4668.CrossRefPubMedPubMedCentral

54.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939–49. https://doi.org/10.1001/jama.2015.4669.CrossRefPubMedPubMedCentral

55.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, et al. Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry. 2018;75:84–95. https://doi.org/10.1001/jamapsychiatry.2017.3391.CrossRefPubMed

56.

Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid Beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15:169–76. https://doi.org/10.1159/000068478.CrossRefPubMed

57.

Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, et al. Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ study. Alzheimers Dement. 2013;9:199–203.CrossRef

58.

Skoog I, Kern S, Zetterberg H, Östling S, Börjesson-Hanson A, Guo X, et al. Low cerebrospinal fluid Aβ42 and Aβ40 are related to white matter lesions in cognitively Normal elderly. J Alzheimers Dis. 2018;62:1877–86. https://doi.org/10.3233/JAD-170950.CrossRefPubMedPubMedCentral

59.

Skoog I, Palmertz B, Andreasson LA. The prevalence of white-matter lesions on computed tomography of the brain in demented and nondemented 85-year-olds. J Geriatr Psychiatry Neurol. 1994;7:169–75. https://doi.org/10.1177/089198879400700308.CrossRefPubMed

60.

Bennett IJ, Greenia DE, Maillard P, Sajjadi SA, DeCarli C, Corrada MM, et al. Age-related white matter integrity differences in oldest-old without dementia. Neurobiol Aging. 2017;56:108–14. https://doi.org/10.1016/j.neurobiolaging.2017.04.013.CrossRefPubMedPubMedCentral

61.

Engels MMA, van der Flier WM, Stam CJ, Hillebrand A, Scheltens P, van Straaten ECW. Alzheimer’s disease: the state of the art in resting-state magnetoencephalography. Clin Neurophysiol. 2017;128:1426–37. https://doi.org/10.1016/j.clinph.2017.05.012.CrossRefPubMed

62.

Morris J. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.CrossRef

63.

Folstein M, Robins L, Helzer J. The mini-mental state examination. Arch Gen Psychiatry. 1983;40:812.CrossRef

64.

Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94. https://doi.org/10.1111/j.1365-2796.2004.01388.x.CrossRefPubMed

65.

McKhann G, Drachman D, Folstein M, Katzman R. Clinical diagnosis of Alzheimer’s disease: report of the MINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Forse on Alzheimer’s disease. Neurology. 1984;34:939. https://doi.org/10.3233/JAD-122299.CrossRef

66.

Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49. https://doi.org/10.1016/0022-3956(82)90033-4.CrossRefPubMed

67.

Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.CrossRef

68.

Jakobsson U. Using the 12-item short form health survey (SF-12) to measure quality of life among older people. Aging Clin Exp Res. 2007;19:457–64.CrossRef

69.

Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006;67:834–42. https://doi.org/10.1212/01.wnl.0000234032.77541.a2.CrossRefPubMedPubMedCentral

70.

Vellas B, Villars H, Abellan G, Soto ME, Rolland Y, Guigoz Y, et al. Overview of the MNA – It’s history and challenges. J Nutr. 2006;10:456–65.

71.

Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131:485–91.CrossRef

72.

Landau SM, Marks SM, Mormino EC, Rabinovici GD, Oh H, O’Neil JP, et al. Association of Lifetime Cognitive Engagement and low β-amyloid deposition. Arch Neurol. 2012;69:623–9. https://doi.org/10.1001/archneurol.2011.2748.CrossRefPubMedPubMedCentral

73.

Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurol. 2005;65:559–64. https://doi.org/10.1212/01.wnl.0000172958.95282.2a.CrossRef

74.

Sikkes SA, Knol DL, Pijnenburg YA, de Lange-de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL questionnaire©, a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 2013;41:35–41. https://doi.org/10.1159/000346277.CrossRefPubMed

75.

Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, et al. Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL questionnaire. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2017;8:26–35. https://doi.org/10.1016/j.dadm.2017.03.002.CrossRef

76.

Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–9. https://doi.org/10.1176/jnp.12.2.233.CrossRefPubMed

77.

Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin S-C, Bieniek K, et al. Validation of the Mayo sleep questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011;12:445–53. https://doi.org/10.1016/j.sleep.2010.12.009.CrossRefPubMedPubMedCentral

78.

Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46:153–62.CrossRef

79.

Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. Journals Gerontol. 1982;37:323–9. https://doi.org/10.1093/geronj/37.3.323.CrossRef

80.

Reijnierse EM, de Jong N, Trappenburg MC, Blauw GJ, Butler-Browne G, Gapeyeva H, et al. Assessment of maximal handgrip strength: how many attempts are needed? J Cachexia Sarcopenia Muscle. 2017;8:466–74. https://doi.org/10.1002/jcsm.12181.CrossRefPubMedPubMedCentral

81.

Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, et al. Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace. 2014;16:1291–5. https://doi.org/10.1093/europace/euu057.CrossRefPubMedPubMedCentral

82.

Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556–62.CrossRef

83.

Al-Qaisi M, Nott DM, King DH, Kaddoura S. Ankle brachial pressure index (ABPI): an update for practitioners. Vasc Health Risk Manag. 2009;5:833–41. https://doi.org/10.2147/VHRM.S6759.CrossRefPubMedPubMedCentral

84.

Mayer MA, Hornegger J, Mardin CY, Tornow RP. Retinal nerve fiber layer segmentation on FD-OCT scans of normal subjects and glaucoma patients. Biomed Opt Express. 2010;1:1358–83.CrossRef

85.

Cheung CY, Hsu W, Lee ML, Wang JJ, Mitchell P, Lau QP, et al. A new method to measure peripheral retinal vascular caliber over an extended area. Microcirculation. 2010;17:495–503. https://doi.org/10.1111/j.1549-8719.2010.00048.x.CrossRefPubMed

86.

Smits C, Theo Goverts S, Festen JM. The digits-in-noise test: assessing auditory speech recognition abilities in noise. J Acoust Soc Am. 2013;133:1693–706. https://doi.org/10.1121/1.4789933.CrossRefPubMed

87.

Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. “Sniffin” sticks’. Olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses. 1997;22:39–52. https://doi.org/10.1093/chemse/22.1.39.CrossRefPubMed

88.

Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, et al. The central biobank and virtual biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases. Front Neurol. 2015;6:216. https://doi.org/10.3389/fneur.2015.00216.CrossRefPubMedPubMedCentral

89.

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41:1088–93. https://doi.org/10.1038/ng.440.CrossRefPubMedPubMedCentral

90.

Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41:1094–9.CrossRef

91.

Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452–8.CrossRef

92.

Shulman JM, Chen K, Keenan BT, Chibnik LB, Fleisher A, Thiyyagura P, et al. Genetic susceptibility for Alzheimer’s disease Neuritic plaque pathology. JAMA Neurol. 2013;70:1150–7. https://doi.org/10.1001/jamaneurol.2013.2815.CrossRefPubMedPubMedCentral

93.

Cardenas VA, Reed B, Chao LL, Chui H, Sanossian N, Decarli CC, et al. Associations among vascular risk factors, carotid atherosclerosis, and cortical volume and thickness in older adults. Stroke. 2012;43:2865–70. https://doi.org/10.1161/STROKEAHA.112.659722.CrossRefPubMedPubMedCentral

94.

Van Sloten TT, Schram MT, Van Den Hurk K, Dekker JM, Nijpels G, Henry RMA, et al. Local stiffness of the carotid and femoral artery is associated with incident cardiovascular events and all-cause mortality: the Hoorn study. J Am Coll Cardiol. 2014;63:1739–47. https://doi.org/10.1016/j.jacc.2013.12.041.CrossRefPubMed

95.

Moneta GL, Edwards JM, Chitwood RW, Taylor LM, Lee RW, Cummings CA, et al. Correlation of north American symptomatic carotid endarterectomy trial (NASCET) angiographic definition of 70 to 99% internal carotid artery stenosis with duplex scanning. J Vasc Surg. 1993;17:152–9.CrossRef

96.

Wierenga CE, Hays CC, Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer’s disease. J Alzheimers Dis. 2014;42(Suppl 4):S411–9. https://doi.org/10.3233/JAD-141467.CrossRefPubMedPubMedCentral

97.

Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–8. https://doi.org/10.1006/nimg.1996.0066.CrossRefPubMed

98.

Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279–87. https://doi.org/10.1006/nimg.1997.0303.CrossRefPubMed

99.

Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22:1440–52.CrossRef

100.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29. https://doi.org/10.1002/ana.22068.CrossRefPubMed

101.

Hillebrand A, Barnes GR, Bosboom JL, Berendse HW, Stam CJ. Frequency-dependent functional connectivity within resting-state networks: an atlas-based MEG beamformer solution. Neuroimage. 2012;59:3909–21. https://doi.org/10.1016/j.neuroimage.2011.11.005.CrossRefPubMedPubMedCentral

102.

Fernández A, Hornero R, Mayo A, Poza J, Gil-Gregorio P, Ortiz T. MEG spectral profile in Alzheimer’s disease and mild cognitive impairment. Clin Neurophysiol. 2006;117:306–14. https://doi.org/10.1016/j.clinph.2005.10.017.CrossRefPubMed

103.

de Haan W, van der Flier WM, Koene T, Smits LL, Scheltens P, Stam CJ. Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer’s disease. Neuroimage. 2012;59:3085–93.CrossRef

104.

Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J Neurol Sci. 2010;289:128–34.CrossRef

105.

Jefferis JM, Taylor JP, Collerton J, Jagger C, Kingston A, Davies K, et al. The association between diagnosed glaucoma and cataract and cognitive performance in very old people: cross-sectional findings from the Newcastle 85+ study. Ophthalmic Epidemiol. 2013;20:82–8. https://doi.org/10.3109/09286586.2012.757626.CrossRefPubMedPubMedCentral

106.

Dato S, Soerensen M, Lagani V, Montesanto A, Passarino G, Christensen K, et al. Contribution of genetic polymorphisms on functional status at very old age: a gene-based analysis of 38 genes (311 SNPs) in the oxidative stress pathway. Exp Gerontol. 2014;52:23–9. https://doi.org/10.1016/j.exger.2014.01.014.CrossRefPubMedPubMedCentral

107.

Soerensen M, Christensen K, Stevnsner T, Christiansen L. The Mn-superoxide dismutase single nucleotide polymorphism rs4880 and the glutathione peroxidase 1 single nucleotide polymorphism rs1050450 are associated with aging and longevity in the oldest old. Mech Ageing Dev. 2009;130:308–14. https://doi.org/10.1016/j.mad.2009.01.005.CrossRefPubMedPubMedCentral

108.

Mengel-From J, Christensen K, McGue M, Christiansen L. Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiol Aging. 2011;32:554 e7–11. https://doi.org/10.1016/j.neurobiolaging.2010.07.016.CrossRef

109.

Dato S, Krabbe KS, Thinggaard M, Pedersen BK, Christensen K, Bruunsgaard H, et al. Commonly studied polymorphisms in inflammatory cytokine genes show only minor effects on mortality and related risk factors in nonagenarians. J Gerontol A Biol Sci Med Sci. 2010;65:225–35. https://doi.org/10.1093/gerona/glp210.CrossRefPubMed

110.

Mengel-From J, Thinggaard M, Lindahl-Jacobsen R, McGue M, Christensen K, Christiansen L. CLU genetic variants and cognitive decline among elderly and oldest old. PLoS One. 2013;8:e79105. https://doi.org/10.1371/journal.pone.0079105.CrossRefPubMedPubMedCentral

111.

Bathum L, von Bornemann HJ, Christiansen L, McGue M, Jeune B, Christensen K. Methylenetetrahydrofolate reductase 677C>T and methionine synthase 2756A>G mutations: no impact on survival, cognitive functioning, or cognitive decline in nonagenarians. J Gerontol A Biol Sci Med Sci. 2007;62:196–201.CrossRef

112.

Hao Q, Ding X, Gao L, Yang M, Dong B. G-395A polymorphism in the promoter region of the KLOTHO gene associates with reduced cognitive impairment among the oldest old. Age (Omaha). 2016;38:1–8. https://doi.org/10.1007/s11357-015-9869-7.CrossRef

113.

Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Mei W, Yan-Ling Z. Pro12Ala polymorphism in PPAR-γ2 and dementia in Chinese nonagenarians/centenarians. Age (Omaha). 2010;32:397–404. https://doi.org/10.1007/s11357-010-9132-1.CrossRef

114.

Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Tienari P, Niinisto L, et al. Cardiovascular risk factors and Alzheimer’s disease: a genetic association study in a population aged 85 or over. Neurosci Lett. 2000;292:195–8.CrossRef

115.

Morris J, Heyman A, Mohs R, Hughes J, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD) Part I Clinical and neuropsychological assesment of Alzheimer’s disease. Neurology. 1989;39:1159. https://doi.org/10.1212/WNL.39.9.1159.CrossRefPubMed

116.

Abikoff H, Alvir J, Hong G, Sukoff R, Orazio J, Solomon S, et al. Logical memory subtest of the Wechsler memory scale: age and education norms and alternate-form reliability of two scoring systems. J Clin Exp Neuropsychol. 1987;9:435–48. https://doi.org/10.1080/01688638708405063.CrossRefPubMed

117.

Rey A. L’examen clinique en psychologie (the clinical examination in psychology). Paris: Presses Universitaires de France; 1964.

118.

Meyers JE, Bayless JD, Meyers KR. Rey complex figure: memory error patterns and functional abilities. Appl Neuropsychol. 1996;3:89–92. https://doi.org/10.1207/s15324826an0302.CrossRefPubMed

119.

Cronholm B, Viding G. Digit span as a test of immediate memory. Nord Med. 1956;56:1612–4.PubMed

120.

Wechsler D. The psychological corporation. TX: San Antonia; 1997.

121.

Tombaugh T. Normative data stratified by age and education for two measures of verbal fluency FAS and animal naming. Arch Clin Neuropsychol. 1999;14:167–77.PubMed

122.

Royall DR, Cordes JA, Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry. 1998;64:588–94.CrossRef

123.

McKenna PAT, Warrington EK. Testing for nominal dysphasia. J Neurol Neurosurg Psychiatry. 1980;43:781–8.CrossRef

124.

Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–6.CrossRef

125.

Wechsler D. Wechsler adult intelligence scale - revised manual; 1981.

126.

Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994;5:266–81.PubMed

127.

Nelson HE, O’Connell A. Dementia: the estimation of premorbid intelligence levels using the new adult Reading test. Cortex. 1978;14:234–44.CrossRef

128.

Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 2002;73:126–33.CrossRef

129.

Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s cognitive examination revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21:1078–85.CrossRef

Title: Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study
Authors: Nienke Legdeur
Maryam Badissi
Stephen F. Carter
Sophie de Crom
Aleid van de Kreeke
Ralph Vreeswijk
Marijke C. Trappenburg
Mardien L. Oudega
Huiberdina L. Koek
Jos P. van Campen
Carolina J. P. W. Keijsers
Chinenye Amadi
Rainer Hinz
Mark F. Gordon
Gerald Novak
Jana Podhorna
Erik Serné
Frank Verbraak
Maqsood Yaqub
Arjan Hillebrand
Alessandra Griffa
Neil Pendleton
Sophia E. Kramer
Charlotte E. Teunissen
Adriaan Lammertsma
Frederik Barkhof
Bart N. M. van Berckel
Philip Scheltens
Majon Muller
Andrea B. Maier
Karl Herholz
Pieter Jelle Visser
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Geriatrics / Issue 1/2018
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-018-0984-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study

Abstract

Background

Methods

Discussion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Determinants for utilization and transitions of long-term care in adults 65+ in Germany: results from the longitudinal KORA-Age study

Effects of 12-month home-based physiotherapy on duration of living at home and functional capacity among older persons with signs of frailty or with a recent hip fracture - protocol of a randomized controlled trial (HIPFRA study)

Impact of a nurse-based intervention on medication outcomes in vulnerable older adults

Nordic walking training and nutritional supplementation in pre-frail older Indians: an open-labelled experimental pre-test and post-test pilot study to develop intervention model

Key stakeholders’ views on the quality of care and services available to frail seniors in Canada

Dementia as a predictor of care-related quality of life in informal caregivers: a cross-sectional study to investigate differences in health-related outcomes between dementia and non-dementia caregivers

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page